{"slug":"myeloma","tag":"myeloma","variants":["myeloma"],"description":"No description yet","count":14,"kinds":{"person":14},"related":[{"slug":"trialist","tag":"trialist","shared":4},{"slug":"car-t","tag":"car-t","shared":3},{"slug":"bispecific","tag":"bispecific","shared":2},{"slug":"transplant","tag":"transplant","shared":2},{"slug":"adc","tag":"adc","shared":1},{"slug":"bone-disease","tag":"bone-disease","shared":1},{"slug":"community-research","tag":"community-research","shared":1},{"slug":"epidemiology","tag":"epidemiology","shared":1},{"slug":"genomics","tag":"genomics","shared":1},{"slug":"gprc5d","tag":"gprc5d","shared":1},{"slug":"greece","tag":"greece","shared":1},{"slug":"hovon","tag":"hovon","shared":1}],"records":[{"id":"philippe-moreau","kind":"person","name":"Philippe Moreau","route":"/people/philippe-moreau/","tldr":"Led MajesTEC-1 and CASSIOPEIA, bringing the first bispecific antibody and daratumumab quadruplets to myeloma."},{"id":"thierry-facon","kind":"person","name":"Thierry Facon","route":"/people/thierry-facon/","tldr":"Led MAIA, which made daratumumab-lenalidomide-dexamethasone the standard for older patients with myeloma."},{"id":"pieter-sonneveld","kind":"person","name":"Pieter Sonneveld","route":"/people/pieter-sonneveld/","tldr":"Led PERSEUS, which established daratumumab-VRd as the standard for transplant-eligible myeloma."},{"id":"maria-victoria-mateos","kind":"person","name":"María-Victoria Mateos","route":"/people/maria-victoria-mateos/","tldr":"Led ALCYONE and the smouldering myeloma trials that showed treating early can delay progression to active disease."},{"id":"nikhil-munshi","kind":"person","name":"Nikhil C. Munshi","route":"/people/nikhil-munshi/","tldr":"Led KarMMa, which brought idecabtagene vicleucel, the first CAR-T for myeloma, to approval."},{"id":"jesus-berdeja","kind":"person","name":"Jesús G. Berdeja","route":"/people/jesus-berdeja/","tldr":"Led CARTITUDE-1, the trial that brought ciltacabtagene autoleucel, the most active myeloma CAR-T, to approval."},{"id":"sagar-lonial","kind":"person","name":"Sagar Lonial","route":"/people/sagar-lonial/","tldr":"Led SIRIUS and the DREAMM programme, bringing daratumumab monotherapy and the BCMA ADC belantamab to myeloma."},{"id":"noopur-raje","kind":"person","name":"Noopur Raje","route":"/people/noopur-raje/","tldr":"Led the first-in-human trial of BCMA CAR-T (bb2121) in myeloma and studies of bone disease treatment."},{"id":"ajai-chari","kind":"person","name":"Ajai Chari","route":"/people/ajai-chari/","tldr":"Led the pivotal talquetamab trial, establishing GPRC5D as the second bispecific target in myeloma."},{"id":"ola-landgren","kind":"person","name":"C. Ola Landgren","route":"/people/ola-landgren/","tldr":"Showed that MGUS precedes essentially all myeloma and leads MRD-driven trials aiming for cure without transplant."},{"id":"sigurdur-kristinsson","kind":"person","name":"Sigurdur Y. Kristinsson","route":"/people/sigurdur-kristinsson/","tldr":"Leads iStopMM, which screened most of Iceland's adults for myeloma precursors to test whether early detection helps."},{"id":"graham-jackson","kind":"person","name":"Graham H. Jackson","route":"/people/graham-jackson/","tldr":"Led Myeloma XI, the 4,000-patient UK trial that proved lenalidomide maintenance extends survival after transplant."},{"id":"meletios-dimopoulos","kind":"person","name":"Meletios A. Dimopoulos","route":"/people/meletios-dimopoulos/","tldr":"Greek haematologist who led POLLUX and CANDOR, two of the pivotal daratumumab combination trials in relapsed myeloma."},{"id":"michel-attal","kind":"person","name":"Michel Attal","route":"/people/michel-attal/","tldr":"French haematologist whose trials established autologous stem-cell transplantation for myeloma in the 1990s and, in IFM 2009, showed that transplant still adds benefit in the era of lenalidomide, bortezomib and dexamethasone."}]}